Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Journal articles
, 2025, 'Prevalence of Hidradenitis Suppurativa A Meta-Analysis of Global Hidradenitis Suppurativa Atlas Studies', JAMA Dermatology, 161, pp. 1022 - 1028, http://dx.doi.org/10.1001/jamadermatol.2025.2373
, 2025, 'Differentiating the Role of Inflammation in Hidradenitis Suppurativa from that in other Inflammatory Skin Diseases', Journal of Investigative Dermatology, 145, pp. 2417 - 2427, http://dx.doi.org/10.1016/j.jid.2025.04.009
, 2025, 'Evaluating the quality and readability of online information about hidradenitis suppurativa: a systematic review', Clinical and Experimental Dermatology, 50, pp. 1937 - 1944, http://dx.doi.org/10.1093/ced/llaf236
, 2025, 'Food as Medicine in Hidradenitis Suppurativa: A Review of Dietary Effects on Hidradenitis Suppurativa Pathogenesis', Integrative and Complementary Therapies, 31, pp. 181 - 191, http://dx.doi.org/10.1177/27683192251376656
, 2025, 'Quantifying time to medical and/or surgical therapy after diagnosis of hidradenitis suppurativa and pilonidal sinus disease: A propensity-matched real-world cohort analysis', Journal of the European Academy of Dermatology and Venereology, 39, pp. e671 - e672, http://dx.doi.org/10.1111/jdv.20494
, 2025, 'Safety and efficacy of biologics in patients with Down syndrome and hidradenitis suppurativa: A retrospective cohort study', Clinical and Experimental Dermatology, 50, pp. 1431 - 1433, http://dx.doi.org/10.1093/ced/llaf090
, 2025, 'Malignancy risk differs between hidradenitis suppurativa and pilonidal sinus disease', Journal of the American Academy of Dermatology, 92, pp. 1381 - 1382, http://dx.doi.org/10.1016/j.jaad.2025.01.076
, 2025, 'The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial', Journal of Investigative Dermatology, 145, pp. 1396 - 1406.e6, http://dx.doi.org/10.1016/j.jid.2024.10.602
, 2025, 'Comparison of Keratinocyte Cancer Tumour and Defect Sizes Treated by Mohs Micrographic Surgery: Sydney Versus Outside Metropolitan Sydney', Australasian Journal of Dermatology, 66, pp. e148 - e154, http://dx.doi.org/10.1111/ajd.14453
, 2025, 'Infectious complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis', International Journal of Dermatology, 64, pp. 830 - 848, http://dx.doi.org/10.1111/ijd.17527
, 2025, 'Systematic review and meta-analysis of non-SCORTEN predictors of mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis', International Journal of Dermatology, 64, pp. 849 - 860, http://dx.doi.org/10.1111/ijd.17529
, 2025, 'Full spectrum town halls for hidradenitis suppurativa: A model for advancing clinician-patient-researcher engagement in clinical and translational research', Journal of Clinical and Translational Science, 9, http://dx.doi.org/10.1017/cts.2025.62
, 2025, 'Hidradenitis Suppurativa: Pathogenesis and Inflammatory Pathways', Dermatologic Clinics, 43, pp. 179 - 191, http://dx.doi.org/10.1016/j.det.2024.12.004
, 2025, 'Australasian hidradenitis suppurativa management guidelines', Australasian Journal of Dermatology, 66, pp. 75 - 89, http://dx.doi.org/10.1111/ajd.14388
, 2025, 'Unravelling the complex pathogenesis of hidradenitis suppurativa', British Journal of Dermatology, 192, pp. i3 - i14, http://dx.doi.org/10.1093/bjd/ljae238
, 2025, 'Discrepancies in hidradenitis suppurativa lesion characterization by providers and patients', Journal of the European Academy of Dermatology and Venereology, 39, pp. 210 - 220, http://dx.doi.org/10.1111/jdv.19999
, 2025, 'Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens', Journal of Investigative Dermatology, 145, pp. 50 - 55, http://dx.doi.org/10.1016/j.jid.2024.02.041
, 2025, '61257 The Clinical and Molecular Response of Pyoderma Gangrenosum to Interleukin 23 Blockade: Result from a proof-of-concept open-label clinical trial', Journal of the American Academy of Dermatology, 93, pp. AB313 - AB313, http://dx.doi.org/10.1016/j.jaad.2025.05.1236
, 2025, '61380 Predictors of wound healing after surgical deroofing in Hidradenitis Suppurativa', Journal of the American Academy of Dermatology, 93, pp. AB72 - AB72, http://dx.doi.org/10.1016/j.jaad.2025.05.292
, 2025, '62297 Resolution of deep dermal inflammatory lesions with the Nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa (HS): preclinical results and outcomes from the Phase 2 MIRA trial', Journal of the American Academy of Dermatology, 93, pp. AB290 - AB290, http://dx.doi.org/10.1016/j.jaad.2025.05.1146
, 2025, '62305 IHS4-100 responses and other IHS4 outcomes with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial', Journal of the American Academy of Dermatology, 93, pp. AB221 - AB221, http://dx.doi.org/10.1016/j.jaad.2025.05.878
, 2025, '64414 Bimekizumab impact on draining tunnel reduction over 2 years in moderate to severe hidradenitis suppurativa: Results from BE HEARD EXT', Journal of the American Academy of Dermatology, 93, pp. AB137 - AB137, http://dx.doi.org/10.1016/j.jaad.2025.05.546
, 2025, '65 Statin Therapy Is Associated With a Reduced Risk of Autoimmune Blistering Diseases: A Global Retrospective Cohort Study of 172 Million Individuals', Journal of Investigative Dermatology, 145, pp. e42, http://dx.doi.org/10.1016/j.jid.2025.09.083
, 2024, 'Intrinsic factors in the pathogenesis of hidradenitis suppurativa: Genetics, hormones, and the microbiome', Journal of the American Academy of Dermatology, 91, pp. S12 - S16, http://dx.doi.org/10.1016/j.jaad.2024.08.052
, 2024, 'Predictors of wound healing after surgical deroofing in Hidradenitis Suppurativa', Australasian Journal of Dermatology, 65, pp. 636 - 641, http://dx.doi.org/10.1111/ajd.14375
, 2024, 'Quality-of-life evaluation in hidradenitis suppurativa in Australia: Validation and outcomes of the HiSQOL questionnaire', Australasian Journal of Dermatology, 65, pp. 630 - 635, http://dx.doi.org/10.1111/ajd.14370
, 2024, 'Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient-reported ethnicity', Australasian Journal of Dermatology, 65, pp. 560 - 566, http://dx.doi.org/10.1111/ajd.14343
, 2024, 'Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer', The New England Journal of Medicine, 391, pp. 1413 - 1425, http://dx.doi.org/10.1056/nejmoa2403365
, 2024, 'Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized double-blind placebo-controlled clinical trial', British Journal of Dermatology, 191, pp. 508 - 518, http://dx.doi.org/10.1093/bjd/ljae144
, 2024, 'Lichenoid drug reaction to technicium-99: a case report and review of the literature', International Journal of Women S Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000179
, 2024, 'A systematic review of case–control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis', Australasian Journal of Dermatology, 65, pp. 491 - 504, http://dx.doi.org/10.1111/ajd.14329
, 2024, 'An analysis of a 2 × 2 Keyfitz–Kranzer type balance system with varying generalized Chaplygin gas', Physics of Fluids, 36, pp. 096132, http://dx.doi.org/10.1063/5.0231413
, 2024, 'Drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis', Journal of the American Academy of Dermatology, 91, pp. 170 - 172, http://dx.doi.org/10.1016/j.jaad.2024.03.028
, 2024, 'Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients with Epilepsy', JAMA Dermatology, 160, pp. 631 - 640, http://dx.doi.org/10.1001/jamadermatol.2024.1037
, 2024, 'Tissue comparability and bias in hidradenitis suppurativa transcriptomic studies', Proceedings of the National Academy of Sciences of the United States of America, 121, http://dx.doi.org/10.1073/pnas.2404503121
, 2024, 'Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation', Dermatology, 240, pp. 494 - 506, http://dx.doi.org/10.1159/000534575
, 2024, 'Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.15087
, 2024, 'More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence', Journal of the American Academy of Dermatology, 90, pp. e171 - e173, http://dx.doi.org/10.1016/j.jaad.2023.11.064
, 2024, 'Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al.', Australasian Journal of Dermatology, 65, pp. e81 - e84, http://dx.doi.org/10.1111/ajd.14221
, 2024, 'Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial', Journal of Investigative Dermatology, 144, pp. 786 - 793.e1, http://dx.doi.org/10.1016/j.jid.2023.10.005
, 2024, 'Comment on Kridin et al.—Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis', Journal of the European Academy of Dermatology and Venereology, 38, pp. e351 - e353, http://dx.doi.org/10.1111/jdv.19615
, 2024, 'Global consensus process to establish a core dataset for hidradenitis suppurativa registries', British Journal of Dermatology, 190, pp. 510 - 518, http://dx.doi.org/10.1093/bjd/ljad454
, 2024, 'The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa', Journal of the European Academy of Dermatology and Venereology, 38, pp. e348 - e350, http://dx.doi.org/10.1111/jdv.19611
, 2024, 'Hidradenitis suppurativa: New insights into disease mechanisms and an evolving treatment landscape', British Journal of Dermatology, 190, pp. 149 - 162, http://dx.doi.org/10.1093/bjd/ljad345
, 2024, 'Rapid Attenuation of B-Cell and IFN-γ–Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 144, pp. 416 - 419.e5, http://dx.doi.org/10.1016/j.jid.2023.07.023
, 2024, 'Clinical reports: the overarching home for case series and case reports in the BJD', British Journal of Dermatology, 190, pp. 1 - 2, http://dx.doi.org/10.1093/bjd/ljad301
, 2024, 'Laser capture microdissection provides a novel molecular profile of human primary cutaneous melanoma', Pigment Cell and Melanoma Research, 37, pp. 81 - 89, http://dx.doi.org/10.1111/pcmr.13121
, 2024, 'Mast cells are upregulated in hidradenitis suppurativa tissue, associated with epithelialized tunnels and normalized by spleen tyrosine kinase antagonism', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14894
, 2024, '276 Full Spectrum Town Hall Meetings - Advancing Clinician-Patient-Researcher Engagement for Hidradenitis Suppurativa (HS)', Journal of Clinical and Translational Science, 8, pp. 84 - 84, http://dx.doi.org/10.1017/cts.2024.252
, 2024, '52676 Safety and efficacy over one year of spesolimab treatment in patients with hidradenitis suppurativa (HS): Interim analysis of an open-label extension (OLE) study', Journal of the American Academy of Dermatology, 91, pp. ab83, http://dx.doi.org/10.1016/j.jaad.2024.07.337